Proteomics International Laboratories (ASX:PIQ) Full Year 2024 Results

Key Financial Results

• Revenue: AU$3.57m (up 12% from FY 2023).

• Net loss: AU$6.38m (loss widened by 3.2% from FY 2023).

• AU$0.051 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Proteomics International Laboratories Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 27%. Earnings per share (EPS) also surpassed analyst estimates by 9.5%.

Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Global Life Sciences industry.

Performance of the market in Australia.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Proteomics International Laboratories, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.